Tinnitus: 14.4% of adults worldwide

How many people are affected

The European survey covered 11,427 adults across twelve countries. It shows a threefold spread between countries: 8.7% in Ireland, the lowest rate, against 28.3% in Bulgaria, the highest. Extrapolated to the European Union, it places the number of affected adults at around 65 million, of whom roughly 4 million have a severe form.

The most telling figure in that survey is not a prevalence. It is a care-seeking rate: about 6% of affected people had consulted a doctor about their tinnitus within the year. Between 14.7% prevalence and 6% care-seeking sits a population living with the symptom without ever having had it investigated.

What is demonstrated

The 2020 Cochrane review on cognitive behavioural therapy pooled 28 trials and 2,733 participants. It is the largest evidence base in the whole field.

The minimal clinically important difference on the THI is set at 7 points. The table therefore has to be read line by line, and the second line is the one usually left out: against standard audiological care, the CBT advantage is 5.65 points, which is real, statistically significant, and below the threshold of clinical relevance. CBT clearly beats doing nothing. It marginally beats looking after the hearing properly.

Hearing aids where there is associated hearing loss are recommended by both the American and the European societies. It is worth knowing what that recommendation rests on: a single randomised trial, 91 participants (Cochrane review, 2014). The basis is physiological and clinical, not experimental. It is a reasonable recommendation, it is not strong evidence, and saying so does not weaken the advice, it places it.

What is not demonstrated

The 2014 American guideline is explicit on two points: clinicians should not recommend Ginkgo biloba, melatonin, zinc or other dietary supplements for treating persistent bothersome tinnitus, and should not recommend transcranial magnetic stimulation for routine treatment. The 2019 European multidisciplinary guideline concludes for its part that no drug can generally be recommended for chronic tinnitus.

The transcranial magnetic stimulation case is instructive because it is not a failure, it is a disappearance. The effect exists at one month, it is measurable, and it fades by six months. A treatment whose benefit does not survive six months is not an answer to a condition that lasts years.

The MRI reflex, and what the figures say about it

Tinnitus in one ear almost always triggers the same chain: worry, MRI, waiting for the result. What that chain finds is worth knowing.

The contrast between the two ends of that table is the clinical message of this section. Isolated tinnitus in one ear, with no asymmetric hearing loss, has less than one chance in a thousand of revealing a tumour. Pulsatile tinnitus, beating in time with the heart, has better than three chances in four of having a cause visible on imaging. These are not two versions of the same symptom, they are two different situations calling for two different responses.

The imaging criterion in the American guideline lists four situations: tinnitus localising to one ear, pulsatile tinnitus, focal neurological abnormality, or asymmetric hearing loss. Outside those cases, imaging is not indicated.

Tinnitus and hearing, a strong relationship

The 2022 European survey gives a clear gradient rather than a percentage.

Expressed as odds ratios, marked hearing difficulty against none gives 18.53 for tinnitus in general and 33.21 for bothersome tinnitus. That is the strongest risk factor in the model, far ahead of every other. The practical consequence: a tinnitus work-up without an audiogram is not a work-up.

What the studies do not allow anyone to claim

The figure seen everywhere, that 90% of people with tinnitus have hearing loss, has no verifiable primary source. The solid data are relational, they are the odds ratios above, not a proportion. We will not quote it.

On depression and sleep, caution runs the other way. A 2024 meta-analysis of 62,270 participants finds a significant association with anxiety (OR 1.29; 95% CI 1.02 to 1.64), but not with depression (OR 1.20; 95% CI 0.94 to 1.52, not significant) nor with sleep disturbance (OR 1.35; 95% CI 0.85 to 2.15, not significant). At population level the link is markedly weaker than specialist practice suggests, because that is where the heaviest cases concentrate. It is a recruitment bias, not a contradiction.

Finally, the World Health Organization publishes figures on hearing loss, not on tinnitus. Any tinnitus statistic attributed to the WHO is misattributed.

What delay adds

In England, 594,546 people were waiting for ENT care in June 2026, and only 59.0% were treated within 18 weeks. In Ireland, on 30 July 2026, 46,124 patients were waiting for a first ENT outpatient appointment, 5,277 of them for more than twelve months.

For ordinary tinnitus, that delay is mainly attrition. For pulsatile tinnitus, or tinnitus with asymmetric hearing loss, it is something else: those are the two situations where imaging is indicated, and where waiting postpones the one test that settles the question.

In practice, if this concerns you

Recent tinnitus, in one ear, pulsatile, or accompanied by hearing loss on one side, justifies a work-up without waiting. Long-standing tinnitus, in both ears, stable, belongs in a planned work-up, and the first thing to look for there is the hearing.

Noria Health arranges a full ENT work-up in Brussels within 24 to 48 hours: pure-tone and speech audiometry, otological examination, and imaging only if one of the four criteria above is present. The report is issued within 24 hours, follow-up is structured at D14, D30 and D90. What Noria Health does not do: promise that tinnitus will go away. No treatment available today achieves that reliably, and saying so is part of the work-up.

Further reading

• Hearing: 430 million people need hearing care
• Vertigo: only 8% of patients get the treatment that works
• Snoring and sleep apnoea, a cardiovascular risk worth testing for

Sources

1. Jarach CM, Lugo A, Scala M, et al. Global prevalence and incidence of tinnitus, a systematic review and meta-analysis. JAMA Neurology, 2022;79:888-900. https://doi.org/10.1001/jamaneurol.2022.2189
2. Biswas R, Lugo A, Akeroyd MA, et al. Tinnitus prevalence in Europe, a multi-country cross-sectional population study. The Lancet Regional Health Europe, 2022;12:100250. https://doi.org/10.1016/j.lanepe.2021.100250
3. Fuller T, Cima R, Langguth B, et al. Cognitive behavioural therapy for tinnitus. Cochrane Database of Systematic Reviews, 2020, CD012614. https://doi.org/10.1002/14651858.CD012614.pub2
4. Hoare DJ, Edmondson-Jones M, Sereda M, et al. Amplification with hearing aids for patients with tinnitus and co-existing hearing loss. Cochrane Database of Systematic Reviews, 2014, CD010151. https://doi.org/10.1002/14651858.CD010151.pub2
5. Sereda M, Xia J, Scutt P, et al. Ginkgo biloba for tinnitus. Cochrane Database of Systematic Reviews, 2022, CD013514. https://doi.org/10.1002/14651858.CD013514.pub2
6. Sereda M, Xia J, El Refaie A, et al. Sound therapy (using amplification devices and or sound generators) for tinnitus. Cochrane Database of Systematic Reviews, 2018, CD013094. https://doi.org/10.1002/14651858.CD013094.pub2
7. He Z, Liao D, Ji Q, et al. Efficacy of repetitive transcranial magnetic stimulation for subjective chronic tinnitus, a randomized controlled trial meta-analysis. Frontiers in Neuroscience, 2025. https://doi.org/10.3389/fnins.2025.1579846
8. Tunkel DE, Bauer CA, Sun GH, et al. Clinical practice guideline, tinnitus. Otolaryngology Head and Neck Surgery, 2014;151(2 Suppl):S1-S40. https://www.entnet.org/quality-practice/quality-products/clinical-practice-guidelines/tinnitus/
9. Cima RFF, Mazurek B, Haider H, et al. A multidisciplinary European guideline for tinnitus, diagnostics, assessment, and treatment. HNO, 2019;67(Suppl 1):10-42. https://doi.org/10.1007/s00106-019-0633-7
10. Javed A, Okoh M, Mughal Z, et al. Incidence of vestibular schwannoma in patients with unilateral tinnitus, a systematic review and meta-analysis. Otology and Neurotology, 2023. https://doi.org/10.1097/MAO.0000000000003987
11. Reznitsky M, Petersen MMBS, West N, et al. Epidemiology of vestibular schwannomas, prospective 40-year data from an unselected national cohort. Clinical Epidemiology, 2019;11:981-986.
12. Espinosa-Sánchez JM, et al. Pulsatile tinnitus, a comprehensive clinical approach to diagnosis and management. Journal of Clinical Medicine, 2025;14:4428. https://doi.org/10.3390/jcm14134428
13. Alkhatib SG, Kandregula S, Flesher K, et al. Imaging of pulsatile tinnitus. RadioGraphics, 2024. https://doi.org/10.1148/rg.240030
14. Yang D, Zhang D, Zhang X, Li X. Tinnitus-associated cognitive and psychological impairments, a comprehensive review meta-analysis. Frontiers in Neuroscience, 2024. https://doi.org/10.3389/fnins.2024.1275560
15. NHS England. Consultant-led referral to treatment waiting times, RTT data 2026-27, June 2026. https://www.england.nhs.uk/statistics/statistical-work-areas/rtt-waiting-times/rtt-data-2026-27/
16. National Treatment Purchase Fund. Outpatient waiting list by specialty, 30 July 2026. https://www.ntpf.ie/waiting-list-data/open-data/

See also: all our articles on ENT.

Have your case reviewed. Noria Health arranges a specialist consultation near Brussels and confirms feasibility within 24 to 48 hours. Open a case.